SLU-PP-32
Contents
- Quickstart Highlights
- Dosing & Reconstitution Guide
- Murine-Equivalent Protocol (3 mL = ~1.67 mg/mL)
- Reconstitution Steps
- Supplies Needed
- Protocol Overview
- Dosing Protocol
- Storage Instructions
- Important Notes
- How This Works
- Preclinical Observations
- Administration Technique
- Injection Technique
- Recommended Source
- Important Note
- References
Quickstart Highlights
\SLU-PP-332 is a synthetic research compound classified as a pan-agonist of estrogen-related receptors (ERRα, ERRβ, and ERRγ). It has been studied exclusively in preclinical (murine) models, where it demonstrated the ability to activate gene pathways associated with aerobic exercise, enhance mitochondrial performance, and improve endurance and metabolic function.
At present, no human clinical trials have been conducted, and all available data comes from controlled laboratory studies in animals.
- Evidence Base: Preclinical murine studies only (intraperitoneal dosing).
- Reconstitution: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
- Murine Dose Range: ~1250–2500 mcg daily (based on a 25 g mouse), divided into two doses.
- Measurement Guide: 1 unit (0.01 mL) ≈ 16.7 mcg using a U-100 insulin syringe.
- Storage: Lyophilized at −20 °C; reconstituted at 2–8 °C.
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Murine-Equivalent Protocol (3 mL = ~1.67 mg/mL)
| Phase | Daily Dose (mcg) | Per-Injection Dose (mcg) | Units per Injection (mL) |
|---|---|---|---|
| Weeks 1–2 | 1250 mcg | 625 mcg | 37.5 units (0.375 mL) |
| Weeks 3–8 | 2500 mcg | 1250 mcg | 75 units (0.75 mL) |
Route & Frequency:
- Administered twice daily in murine studies
- Route used: Intraperitoneal injection
- No validated data supports once-daily or subcutaneous protocols
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly along the vial wall; avoid foaming.
- Gently swirl or roll until fully dissolved; do not shake.
- Label with reconstitution date and refrigerate at 2–8 °C, protected from light.
- Use within 28 days.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Based on twice-daily administration:
Peptide Vials
- 8 weeks: ~25 vials
- 12 weeks: ~39 vials
- 16 weeks: ~53 vials
Insulin Syringes (U-100):
- 2 injections/day → 14 per week
- 8 weeks: 112 syringes
- 12 weeks: 168 syringes
- 16 weeks: 224 syringes
Bacteriostatic Water (10 mL bottles):
- ~3.0 mL per vial
- 8 weeks: 75 mL → 8 bottles
- 12 weeks: 117 mL → 12 bottles
- 16 weeks: 159 mL → 16 bottles
Alcohol Swabs:
- 2 per injection (vial + site)
- 4 daily → 28 per week
- 8 weeks: 224 swabs
- 12 weeks: 336 swabs
- 16 weeks: 448 swabs
Protocol Overview
- Evidence Status: Preclinical only (no human studies).
- Mechanism: Activates ERR pathways linked to aerobic metabolism.
- Administration: Intraperitoneal injection (murine models).
- Frequency: Twice daily.
- Cycle Duration: ~8 weeks in studies.
- Reconstitution: 3.0 mL per vial (~1.67 mg/mL).
- Storage: Frozen (lyophilized), refrigerated after mixing.
Dosing Protocol
- Weeks 1–2: 1250 mcg daily (625 mcg twice daily)
- Weeks 3–8: 2500 mcg daily (1250 mcg twice daily)
Timing: Maintain consistent intervals between doses.
Storage Instructions
- Lyophilized Powder: Store at −20 °C in a dry, dark environment.
- Reconstituted Solution: Refrigerate at 2–8 °C.
- Avoid repeated freeze–thaw cycles.
- Allow vials to reach room temperature before opening to prevent condensation.
Important Notes
- This compound has no human safety or efficacy data.
- All information is based on animal studies only.
- Use sterile syringes for each administration.
- Maintain detailed logs of dosing and observations.
- Rotate injection sites to reduce irritation.
- Intended strictly for research purposes, not for human use.
How This Works
SLU-PP-332 acts as a pan-agonist of estrogen-related receptors, particularly ERRα, which plays a key role in regulating energy metabolism and mitochondrial function.
In animal studies, activation of these receptors:
- Stimulates gene expression associated with aerobic exercise adaptation
- Enhances mitochondrial respiration and energy production
- Increases fatty acid oxidation in muscle tissue
- Improves endurance and overall metabolic efficiency
Because of these effects, SLU-PP-332 is often described as an “exercise mimetic,” meaning it may replicate some biochemical benefits of physical training without actual exercise stimulus.
Preclinical Observations
Findings observed in murine studies include:
- Metabolic Improvements: Enhanced mitochondrial activity and better glucose handling
- Cardiac Support: Improved heart function via increased fatty acid metabolism
- Endurance Enhancement: Greater running capacity and muscle oxidative performance
- Renal Effects: Reduction in inflammation and mitochondrial dysfunction in aging kidneys
Important: These results are limited to animal models; human relevance is unknown.
Research Considerations
- Outcomes may vary depending on diet, environment, and study conditions.
- Some studies suggest synergistic effects when combined with exercise.
- Accurate dosing and compound handling are critical for reproducibility.
- Environmental factors (temperature, diet composition) should be standardized.
Administration Technique
(Note: Intraperitoneal route used in studies; subcutaneous use is not validated.)
- Clean vial stopper and injection site with alcohol.
- For subcutaneous technique: insert needle at 45–90° into fatty tissue.
- Inject slowly and steadily; do not aspirate.
- Rotate injection sites to prevent tissue irritation.
Recommended Source
We recommend Fit Aminos for high-purity research peptide products.
Why Fit Aminos?
- High-purity, lab-tested peptide batches with quality verification.
- Consistent handling and preparation processes designed to support reliable research protocols.
- Transparent sourcing and dependable fulfillment for research-grade compounds.
Important Note
This content is intended for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment.
SLU-PP-32 remains an investigational peptide with limited human clinical data. For research use only. Not for human consumption.
References
ACS Chemical Biology (2023)
— Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
Journal of Pharmacology and Experimental Therapeutics (2024)
— A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Circulation (2024)
— Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
American Journal of Pathology (2023)
— Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney